Lipoprotein(a) in the Athlete Cardiovascular Workup: Why the Lifetime-Risk Marker That the Standard Lipid Panel Does Not See Is a One-Time-In-A-Lifetime Draw, the 50 mg/dL and 125 nmol/L Thresholds That Separate Low-Hazard From Family-Signal Thresholds, the Paired Read Against ApoB and hs-CRP, and the SOAP Structure That Carries the Lp(a) Finding Into the Dietary, Training, and Referral Branches of the Sports-Nutrition Plan

A 34-year-old male competitive masters-category road cyclist presents to the sports RD at the start of a 24-week build toward a late-summer regional stage race. The intake file carries a pre-camp lipid panel of total cholesterol 182 mg/dL, LDL-C 108 mg/dL, HDL-C 54 mg/dL, triglycerides 92 mg/dL — every marker within the laboratory reference bracket. The resting ECG from the sports-medicine clearance appointment carries no abnormalities. The cardiovascular section of the family-history intake carries two documented first-degree events on the maternal side — a mother who sustained an acute MI at age 54 and a maternal uncle who received a drug-eluting stent at age 48 — against a clean paternal-side history. The primary-care read on the panel returned "lipid profile within reference, cardiovascular risk low, cleared to compete for the season."

The read is defensible against the markers that were drawn. The problem is that the marker that carries the familial early-event cardiovascular signal in this presentation has not been drawn. The marker is lipoprotein(a), the standard lipid panel does not include it, and the sports RD who inherits this intake without a line in the plan for the Lp(a) workup is leaving the single lipid marker that cannot be moved by dietary or training intervention — and that reads a lifetime attributable risk roughly comparable to a parent having an early event itself — on the table and off the chart.

This is the lipoprotein(a) interpretation guide for the sports RD: what Lp(a) actually measures at the lipoprotein-particle level and why it is biologically distinct from LDL-C despite the shared particle architecture, the once-in-a-lifetime measurement cadence that the published consensus guidelines (ESC/EAS and the NLA) anchor against the genetic determinism of the marker, the mass-concentration and particle-concentration assay standards and the 30/50/125 threshold brackets that structure the risk read, the paired read against ApoB and hs-CRP that separates isolated-Lp(a)-elevation from compound-high-risk configurations, the four athlete-population presentations that earn the one-time draw at intake, and the SOAP structure that carries the Lp(a) finding into the dietary, training-prescription, supplementation, and sports-cardiology-referral branches of the sports-nutrition plan.

What Lp(a) Actually Measures

Lipoprotein(a) is an LDL-like particle with a single apolipoprotein(a) protein covalently bound by a disulfide bridge to the apoB-100 on the particle surface. The particle carries a cholesterol-rich core identical to the LDL core, but the apo(a) protein attached to the surface changes the particle's atherogenic and thrombogenic properties in ways the LDL-C number does not read. The apo(a) protein carries a plasminogen-homologous kringle-domain structure that competes with plasminogen at the fibrin-clot surface and inhibits fibrinolysis, and the apo(a) attachment produces an oxidized-phospholipid-carrying particle that is independently atherogenic through a mechanism that does not require the LDL-C elevation to be present.

The clinical consequence is that an athlete can carry a normal LDL-C of 108 mg/dL, a normal total cholesterol, a normal triglyceride, a reassuring HDL-C — the complete clean-lipid-panel presentation — and still carry a lifetime attributable cardiovascular risk that is three to four times above population baseline because the Lp(a) particle is contributing an atherogenic and thrombogenic burden that the LDL-C assay cannot see. The Lp(a) signal is independent of the LDL-C signal, independent of the triglyceride signal, and independent of the HDL-C signal. The lipid panel misses it by assay design.

The second clinically important property is that Lp(a) concentration is almost entirely genetically determined by the LPA gene on chromosome 6, with a heritability estimate above 90 percent and a within-individual coefficient of variation across the life course of less than 10 percent. The marker does not move materially with dietary intervention, does not move with exercise training, does not move with the statins that lower LDL-C by 40 to 50 percent, and moves only modestly (and inconsistently) with the PCSK9 inhibitors. The Lp(a) a person carries at age 20 is approximately the Lp(a) that person will carry at age 60.

The Once-in-a-Lifetime Measurement Cadence

The combined ESC/EAS 2022 consensus statement and the National Lipid Association's Lp(a) scientific statement both anchor the measurement cadence at once in a lifetime, with the first draw recommended at or before the first adult cardiovascular risk assessment and typically no repeat measurement required thereafter unless an interventional therapy specific to Lp(a) is initiated. The genetic determinism of the marker makes repeat measurement across years clinically redundant and makes the age-of-first-draw the key decision variable for the sports RD.

The sports-RD-adjacent corollary is that the Lp(a) draw at athlete intake is a one-time clinical investment that structures the next thirty years of cardiovascular-risk framing for that athlete, that cannot be redone from scratch after the fact if it is skipped at intake, and that is the single most cost-effective lipid-panel addition the sports-nutrition practice can standardize in the clinical workup.

The Assay Standards and the Threshold Brackets

Lp(a) is reported in one of two concentration units — mass concentration (mg/dL, measuring the whole lipoprotein particle including apo(a) and cholesterol) or particle concentration (nmol/L, measuring the number of circulating Lp(a) particles independent of particle size). The two scales do not convert cleanly because the apo(a) protein varies in isoform size — the number of kringle IV type 2 (KIV-2) repeats differs across the LPA alleles and the mass concentration therefore does not map linearly to the particle concentration across individuals.

The reference labs now report Lp(a) in nmol/L by preference because the particle-concentration assay is isoform-independent and the published outcome literature anchors the risk thresholds more defensibly on the particle-concentration scale. The sports RD confirms which scale the reporting lab uses and reads the threshold brackets accordingly.

Lp(a) below 30 mg/dL or below 75 nmol/L. The low-risk bracket. The circulating Lp(a) is low enough that the particle is not making a material contribution to the atherogenic or thrombogenic burden above the LDL-C and triglyceride-rich-remnant signal. The sports RD treats this bracket as a reassuring read, closes the Lp(a) workup, and does not reorder.

Lp(a) between 30 and 50 mg/dL or between 75 and 125 nmol/L. The intermediate bracket. The particle is making a measurable but modest contribution to the cardiovascular risk, and the sports RD pairs the Lp(a) read against the ApoB and hs-CRP read to decide whether the compound profile warrants a tighter dietary, lifestyle, and training-side risk-reduction package than the Lp(a) number alone would trigger.

Lp(a) between 50 and 180 mg/dL or between 125 and 430 nmol/L. The high-risk bracket. The particle is making a substantial contribution to the lifetime cardiovascular risk, approximately doubling the attributable hazard above the general-population baseline. The sports RD coordinates a sports-cardiology referral for the cardiology-side risk-stratification work (coronary artery calcium scoring, in some cases CT angiography, and the ApoB-aggressive LDL-C target revision), lays out the dietary and training-side risk-reduction package that is cumulative across the ApoB and hs-CRP axes, and documents the Lp(a) finding and the referral in the SOAP for the athlete's long-horizon cardiovascular file.

Lp(a) above 180 mg/dL or above 430 nmol/L. The very-high-risk bracket. The particle contribution is comparable in magnitude to a heterozygous familial-hypercholesterolemia genotype, the attributable lifetime cardiovascular risk is approximately three to four times the population baseline, and the sports-cardiology referral is urgent and structured. The sports RD coordinates the referral, documents the family-history and personal-presentation context, and ensures the athlete's long-term cardiovascular-risk file carries the Lp(a) finding across every subsequent intake and clearance appointment.

The Paired Read Against ApoB and hs-CRP

Lp(a) is the lifetime-genetic-risk signal, ApoB is the total-atherogenic-particle-count signal, and hs-CRP is the systemic-inflammatory-tone signal. The three markers read independent axes of the cardiovascular-risk picture and the paired read structures the sports-RD intervention differently across the configurations.

High Lp(a), low ApoB, low hs-CRP. The isolated-genetic-Lp(a) configuration. The athlete carries the lifetime genetic hazard but the particle-count and inflammatory-tone axes are not compounding the risk. The sports RD coordinates the sports-cardiology referral, lays out a cumulative lifetime risk-reduction package centered on the dietary and training-side axes (fiber-forward dietary pattern, strict control of the ApoB and hs-CRP axes across the life course, no tobacco, controlled resting blood pressure), and does not escalate the ApoB-reduction target because the particle-count axis is already clean.

High Lp(a), high ApoB, low hs-CRP. The compound-particle-burden configuration. The lifetime genetic hazard is compounded by an elevated total atherogenic particle count, and the sports RD coordinates with sports cardiology on a more aggressive ApoB-reduction target (statin consideration, dietary saturated-fat and dietary-cholesterol reductions, soluble-fiber increase, dietary-pattern-shift toward Mediterranean or DASH-style patterns), with the clinical understanding that moving ApoB does not move Lp(a) but does meaningfully reduce the compound particle-burden hazard.

High Lp(a), low ApoB, high hs-CRP. The compound-inflammatory configuration. The lifetime genetic hazard is compounded by an elevated systemic inflammatory tone, and the sports RD investigates the hs-CRP source — chronic training-load inflammation, dietary pattern (ultra-processed-food vehicles, refined carbohydrate load, inadequate omega-3), occult infection, periodontal disease — and layers the inflammatory-tone reduction interventions on top of the Lp(a) risk-management framework. The hs-CRP axis is movable where the Lp(a) axis is not, and the ROI on the inflammatory-tone intervention is high in this configuration.

High Lp(a), high ApoB, high hs-CRP. The compound-high-risk configuration. All three axes are contributing to the cardiovascular hazard and the sports-cardiology referral is urgent, structured, and paired with a maximally aggressive dietary, training, and lifestyle risk-reduction package. The sports RD documents each axis's intervention plan and the follow-up cadence on each axis independently.

The Four Intake Presentations That Earn the One-Time Lp(a) Draw

Any athlete with a first-degree family history of early cardiovascular events (defined as MI, stent, bypass, or ischemic stroke in a parent or sibling before age 55 in males or 65 in females). The hazard that the family history conveys is partially carried by the shared LPA allele that the Lp(a) draw directly measures, and the one-time draw is the single highest-yield addition to the athlete-intake lipid workup in this population.

Any athlete with a personal history of a cardiovascular event — MI, TIA, ischemic stroke, deep-vein thrombosis, pulmonary embolism — or a coronary artery calcium score above the age-and-sex-adjusted 75th percentile. The Lp(a) draw structures the secondary-prevention cardiology-side planning and anchors the sports RD's long-horizon risk-reduction framework.

Any athlete at or above age 30 at first intake into the sports-nutrition practice who has not previously had an Lp(a) measurement documented. The age-30 anchor is the sports-RD-adjacent operationalization of the ESC/EAS "at or before the first adult cardiovascular risk assessment" guidance, biased toward the earlier end of the window to catch the lifetime-risk framing before the first adverse event.

Any athlete with a lipid panel reading an LDL-C or ApoB persistently above the age-and-sex-adjusted population median despite a dietary and training pattern that would normally produce a lower reading. The paired read of the Lp(a) particle on top of the LDL-C axis clarifies whether the elevated total atherogenic particle count is being driven by the LDL-rich-remnant particle pool, the Lp(a) particle pool, or both.

The SOAP Documentation

My structure on the presenting cyclist vignette reads: "Thirty-four-year-old male competitive masters-category road cyclist, week 1 of a 24-week build toward a late-summer regional stage race. Pre-camp lipid panel reads total cholesterol 182 mg/dL, LDL-C 108 mg/dL, HDL-C 54 mg/dL, triglycerides 92 mg/dL — all within laboratory reference. Resting ECG from sports-medicine clearance appointment reads no abnormalities. Family cardiovascular history documents two first-degree events on the maternal side — mother with acute MI at age 54, maternal uncle with drug-eluting stent at age 48 — against a clean paternal-side history. Dietary pattern documents a mixed-omnivorous Mediterranean-leaning pattern with twice-weekly fatty-fish intake and a daily soluble-fiber load above 10 grams; current supplementation stack carries a disclosed-dose EPA-plus-DHA product at 1,500 mg per day and a disclosed-dose magnesium bisglycinate; no tobacco exposure; resting blood pressure at 118/72 mm Hg across the pre-camp monitoring. Draws ordered today: Lp(a) particle concentration (nmol/L, isoform-independent assay via the reference lab), ApoB, hs-CRP. Expected turnaround on the Lp(a) assay is 10 to 14 business days. Working rationale: the clean standard lipid panel does not read the Lp(a) axis and the maternal-side first-degree early-event history is the highest-prior-probability trigger for an elevated LPA-allele-driven Lp(a) particle concentration. The ApoB paired draw structures the compound-particle-burden read if the Lp(a) returns elevated and the hs-CRP paired draw structures the compound-inflammatory read against the sustained chronic-training-load inflammatory signal that the cycling training produces. Plan: panel returning in 10 to 14 days; Lp(a) read against the 30/50/125 nmol/L threshold bracket, with the sports-cardiology referral triggered at the 125 nmol/L threshold and the referral coordinated with the primary care physician; the one-time nature of the Lp(a) draw is documented in the athlete's long-horizon cardiovascular file and does not reappear on the annual intake draw list; dietary-pattern-maintenance plan continues the Mediterranean-leaning pattern and the twice-weekly fatty-fish target; supplementation stack remains unchanged pending the panel return; training prescription remains unchanged pending the panel return and the cardiology-referral workup if any; the athlete is briefed on the once-in-a-lifetime nature of the Lp(a) measurement and the independence of the Lp(a) axis from the lifestyle intervention axes to pre-empt the \"what can I do about my Lp(a)\" question that follows an elevated return."

The assessment line names the pattern as "maternal-side early-event family history requires the Lp(a) axis in the intake workup even against a clean standard lipid panel" rather than "lipid panel within reference, cardiovascular risk low." The plan line specifies the Lp(a) particle-concentration assay as the correct instrument and documents the once-in-a-lifetime nature of the draw against the athlete's long-horizon cardiovascular file. The sports-cardiology referral threshold is anchored to a defensible, documented numeric read rather than to a clinical hunch about the family history alone.

The Follow-Up Cadence

Lp(a) is not redrawn across the life course. The genetic determinism of the marker makes repeat measurement clinically redundant. The sports RD documents the one-time draw in the athlete's long-horizon cardiovascular file and ensures the file carries the finding across subsequent intakes and clearance appointments.

ApoB and hs-CRP are redrawn annually at the off-season baseline draw. The two axes that are movable with the lifestyle intervention are monitored on the annual cadence and the paired read against the fixed Lp(a) number structures each year's risk-reduction package.

Sports-cardiology referral timelines are set at the first intake and tracked. The referral is not deferred to the athlete's primary care unless the primary care is explicitly managing the cardiovascular risk — the sports RD confirms the referral is placed, documents the cardiology-side plan, and reads the coronary artery calcium score and any secondary cardiology workup into the sports-nutrition risk-management framework at the next intake.

Where Calsanova Fits

The Lp(a) workflow depends on the intake carrying the correct family-history and lipid-panel data at the first visit, the interpretive framework that reads the one-time Lp(a) draw against the 30/50/125 nmol/L bracket with the paired ApoB and hs-CRP interpretation, the SOAP template that pre-populates the Lp(a) rationale and the sports-cardiology referral trigger, the long-horizon cardiovascular file structure that carries the one-time Lp(a) finding across every subsequent athlete intake without appearing on the annual redraw list, and the referral-coordination workflow that confirms the sports-cardiology appointment is placed and the cardiology-side plan is read back into the sports-nutrition framework. Calsanova's clinical intake carries the family-history capture that triggers the Lp(a) draw recommendation, the lipid-interpretation module that reads Lp(a) against the paired-marker framework with reference-threshold flagging, the SOAP template pre-populated against the Lp(a)-plus-ApoB-plus-hs-CRP read, the longitudinal cardiovascular file that structures the once-in-a-lifetime draw separately from the annual-redraw lab list, and the referral-coordination workflow that tracks the sports-cardiology appointment and the coronary artery calcium score through to the athlete's next intake.

Ready to move your sports-nutrition clinical workflow into a purpose-built system? [Try Calsanova free for 30 days](/signup?role=dietitian) — no credit card, HIPAA-ready from day one, and the Lp(a) workup runs cleanly against the family-history capture, the paired ApoB and hs-CRP read, the SOAP template, and the long-horizon cardiovascular file that keeps the one-time draw where it belongs.